FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 19:26:59 25/06/2024 BST | ||
| 16.19 EUR | +1.19% |
|
| Current month | -9.70% | ||
| 1 month | -7.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 16.19 | +1.19% |
| 24/06/24 | 16 | -3.79% |
| 21/06/24 | 16.63 | +1.46% |
| 20/06/24 | 16.39 | -1.74% |
| 19/06/24 | 16.68 | +1.28% |
Real-time BOERSE MUENCHEN
Last update June 25, 2024 at 07:26 pm
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2EBM |
| ISIN | DE000GG2EBM6 |
| Date issued | 11/01/2024 |
| Strike | 712.4 $ |
| Maturity | Unlimited |
| Parity | 13.82 : 1 |
| Emission price | 20.7 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.37 € |
|---|---|
| Lowest since issue | 15.21 € |
| Spread | 0.15 € |
| Spread % | 0.92% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
